NASDAQ:ADMA - ADMA Biologics Stock Price, Forecast & News

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

ADMA Biologics Inc (NASDAQ:ADMA) issued its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.04. The biotechnology company earned $7.22 million during the quarter, compared to analysts' expectations of $5.71 million. ADMA Biologics had a negative return on equity of 203.21% and a negative net margin of 260.92%. View ADMA Biologics' Earnings History.

ADMA Biologics is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for ADMA Biologics.

ADMA Biologics issued an update on its FY 2019 Pre-Market earnings guidance on Thursday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $29.2-29.2 million, compared to the consensus revenue estimate of $25.38 million.

6 analysts have issued twelve-month target prices for ADMA Biologics' shares. Their forecasts range from $4.00 to $14.00. On average, they expect ADMA Biologics' stock price to reach $10.20 in the next twelve months. This suggests a possible upside of 206.3% from the stock's current price. View Analyst Price Targets for ADMA Biologics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ADMA Biologics.

News coverage about ADMA stock has been trending somewhat negative on Wednesday, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ADMA Biologics earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near future. View News Stories for ADMA Biologics.

Some companies that are related to ADMA Biologics include Sangamo Therapeutics (SGMO), Oyster Point Pharma (OYST), AVITA MED LTD/S (RCEL), Cellectis (CLLS), Avrobio (AVRO), Rubius Therapeutics (RUBY), Proteon Therapeutics (PRTO), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Atara Biotherapeutics (ATRA), GENFIT S A/ADR (GNFT), MeiraGTx (MGTX), Aptose Biosciences (APTO), Replimune Group (REPL) and Prevail Therapeutics (PRVL).

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Viking Therapeutics (VKTX), Gilead Sciences (GILD), Corbus Pharmaceuticals (CRBP), Verastem (VSTM), Exelixis (EXEL), Micron Technology (MU), Agile Therapeutics (AGRX), NVIDIA (NVDA), Opko Health (OPK) and SCYNEXIS (SCYX).

ADMA Biologics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Schonfeld Strategic Advisors LLC (2.09%), State Street Corp (1.42%), Geode Capital Management LLC (1.21%), Motley Fool Asset Management LLC (0.90%), Goldman Sachs Group Inc. (0.59%) and Jane Street Group LLC (0.28%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Biotest Divestiture Trust, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Institutional Ownership Trends for ADMA Biologics.

ADMA stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Schonfeld Strategic Advisors LLC, CIBC World Markets Inc., Csenge Advisory Group and UBS Group AG. View Insider Buying and Selling for ADMA Biologics.

ADMA stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., State Street Corp, Bank of Montreal Can, Geode Capital Management LLC, California Public Employees Retirement System, Motley Fool Asset Management LLC, Raymond James & Associates and Windsor Creek Advisors LLC. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for ADMA Biologics.

Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADMA stock can currently be purchased for approximately $3.33.

ADMA Biologics has a market capitalization of $197.54 million and generates $16.99 million in revenue each year. The biotechnology company earns $-65,740,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. ADMA Biologics employs 314 workers across the globe.View Additional Information About ADMA Biologics.

The official website for ADMA Biologics is http://www.admabiologics.com/.

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]